Allogene Therapeutics (ALLO) Interest & Investment Income (2021 - 2025)
Allogene Therapeutics (ALLO) has disclosed Interest & Investment Income for 5 consecutive years, with $3.7 million as the latest value for Q4 2025.
- Quarterly Interest & Investment Income rose 20.91% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.3 million through Dec 2025, down 4.29% year-over-year, with the annual reading at $19.3 million for FY2025, 4.29% down from the prior year.
- Interest & Investment Income hit $3.7 million in Q4 2025 for Allogene Therapeutics, down from $3.9 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q3 2024 to a low of $186000.0 in Q4 2021.
- Historically, Interest & Investment Income has averaged $3.3 million across 5 years, with a median of $3.7 million in 2025.
- Biggest five-year swings in Interest & Investment Income: surged 1382.26% in 2022 and later tumbled 51.68% in 2024.
- Year by year, Interest & Investment Income stood at $186000.0 in 2021, then soared by 1382.26% to $2.8 million in 2022, then soared by 127.24% to $6.3 million in 2023, then crashed by 51.68% to $3.0 million in 2024, then rose by 20.91% to $3.7 million in 2025.
- Business Quant data shows Interest & Investment Income for ALLO at $3.7 million in Q4 2025, $3.9 million in Q3 2025, and $6.2 million in Q2 2025.